title: Prospective study of drug-resistant tuberculosis in a Spanish urban population including patients at risk for HIV infection.
abstract: From January 1988 to October 1992, the primary resistance to first-line antituberculous drugs in 501 tuberculous patients was evaluated prospectively. Three-hundred and seventeen patients were HIV-negative and 184 were HIV-positive; these patients had several different clinical forms of tuberculosis. Moreover, the acquired resistance to antituberculous drugs was studied in 295 non-AIDS patients and in 42 AIDS patients with evidence of antecedent tuberculosis treatment. The data indicated that during these five years there was no consistent and clear-cut trend toward greater frequency of primary drug resistance to any of the first-line antituberculous drugs. Primary drug resistance in HIV-positive patients (7.1%) did not differ significantly (p > 0.05) from that found in HIV-negative patients (8.2%). Among HIV-positive patients, the acquired drug resistance pattern was similar to that detected in HIV-negative patients although the frequency of resistance in the former (69%) was significantly higher (p < 0.01). During the study, resistance to isoniazid was almost constant in the acquired-resistance cases and was frequently associated with resistance to other drugs. Furthermore, the acquired resistance to isoniazid was often of a higher level (1 to 10 mg/l) than the primary resistance (0.2 mg/l), and those strains were usually catalase and peroxidase negative.
authors.affiliation: Microbiology Laboratory, Sta. Cruz and San Pablo Hospital, Barcelona, Spain.
authors.forename: V
authors.initials: V
authors.lastname: Ausina
authors.forename: N
authors.initials: N
authors.lastname: Riutort
authors.forename: B
authors.initials: B
authors.lastname: Viñado
authors.forename: J M
authors.initials: JM
authors.lastname: Manterola
authors.forename: J
authors.initials: J
authors.lastname: Ruiz Manzano
authors.forename: C
authors.initials: C
authors.lastname: Rodrigo
authors.forename: L
authors.initials: L
authors.lastname: Matas
authors.forename: M
authors.initials: M
authors.lastname: Giménez
authors.forename: J
authors.initials: J
authors.lastname: Tor
authors.forename: J
authors.initials: J
authors.lastname: Roca
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D015528:HIV Seroprevalence; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D011446:Prospective Studies; D013030:Spain / Q000453:epidemiology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology
chemical_list: D007538:Isoniazid